100 Or More Amino Acid Residues In The Peptide Chain Patents (Class 514/21.2)
-
Publication number: 20150011460Abstract: An alpha1-proteinase inhibitor delays the onset or progression of pulmonary exacerbations. In addition, methods delay the onset or diminish the progression of pulmonary exacerbations by the administration of inhaled alpha1-proteinase inhibitor.Type: ApplicationFiled: November 22, 2012Publication date: January 8, 2015Inventors: Mark Forshag, Royce Waltrip, Les Garlinghouse, William Barnett
-
Patent number: 8926972Abstract: The disclosure provides a novel anti-angiogenesis fusion protein. The present invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component, which have a superior binding capacity with human VEGF and placental growth factor (PIGF). The fusion protein has improved stability, prolonged half-life and the ability to form multivalent interactions with VEGF, and can be used for anti-angiogenesis, treating VEGF related diseases and inhibiting tumor growth.Type: GrantFiled: March 18, 2010Date of Patent: January 6, 2015Assignee: Genor Biopharma Co. LtdInventors: Joe Zhou, Jianyang Zhao, Jiuru Sun, Jun Wang, Shaoxiong Wang, Xinxing Ma, Jun Lin
-
Publication number: 20150004626Abstract: The present invention relates to a method for labeling or targeting cells whose plasma membrane has lost integrity, such as dead cells, such as for discriminating between live cells and cells whose plasma membrane has lost integrity; to an embodiment of the method for determining one or more values of one or more parameters of cells of a biological sample; to use of the method in an assay for screening drugs for therapy such as cancer therapy; to use of the method to monitor and/or determine the effectiveness of a therapy; to an assay kit; to a complex; to the complex for use as a medicament; to the complex for use in treatment of cancer(s) and/or plaque(s) and/or regeneration and/or supporting the immune system; and, to a dead cell.Type: ApplicationFiled: February 6, 2013Publication date: January 1, 2015Inventors: Markwin Hendrik Maring, Clemens Waltherus Gerardus Löwik, Ermond Reijer Van Beek
-
Publication number: 20150004165Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.Type: ApplicationFiled: September 8, 2014Publication date: January 1, 2015Applicant: INCYTE CORPORATIONInventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Kaulback, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J.A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao M. Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Kareht
-
Patent number: 8921310Abstract: The present invention relates to an agent for improving lipid metabolism, a food/drink, and a feed, containing ?s-casein as an active ingredient thereof. In addition, the present invention relates to an agent for suppressing body weight gain, an agent for reducing body fat, and an agent for reducing blood lipid, containing the agent for improving lipid metabolism.Type: GrantFiled: June 5, 2007Date of Patent: December 30, 2014Assignee: Morinaga Milk Industry Co., Ltd.Inventors: Yuuki Somoto, Masayuki Ikeda
-
Patent number: 8920809Abstract: This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject.Type: GrantFiled: August 17, 2010Date of Patent: December 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: Joseph M. Dirienzo
-
Patent number: 8920806Abstract: The present invention relates generally to a method of modulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of modulating an inflammatory response in a mammal by modulating the functional activity of activin and thereby modulating the pro-inflammatory mediator cascade. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by an aberrant, unwanted or otherwise inappropriate inflammatory response including, inter alia, sepsis and inflammation of the airway. The present invention is further directed to methods for identifying and/or designing agents capable of modulating activin mediated regulation of the inflammatory response.Type: GrantFiled: October 6, 2004Date of Patent: December 30, 2014Assignee: Paranta Biosciences LimitedInventors: David Morritz De Kretser, David James Phillips, Kristian Lee Jones, Robyn O'Hehir, Shane Patella
-
Publication number: 20140377225Abstract: The present invention comprises a method of improving bone health and muscle health in a companion animal comprising administering a composition comprising a fatty acid component to the companion animal wherein the fatty acid component comprises a ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) from about 3:1 to about 25:1. The present invention additionally comprises a composition comprising a fatty acid component comprising docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) wherein the ratio of docosahexaenoic acid (DHA) to eicosapentaenoic acid (EPA) is from about 3:1 to about 25:1.Type: ApplicationFiled: September 8, 2014Publication date: December 25, 2014Inventors: Bruce Alan Watkins, Kevin Mark Hannon, Allan John Lepine
-
Publication number: 20140378371Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: April 21, 2014Publication date: December 25, 2014Applicant: Symthera Canada Ltd.Inventors: Chai Ezerzer, Nicholas Harris
-
Patent number: 8912147Abstract: The invention provides fusion protein constructs comprising a functional mitochondrial protein and methods of treating mitochondrial disorders by the fusion proteins and compositions thereof.Type: GrantFiled: September 23, 2013Date of Patent: December 16, 2014Assignee: BioBlast Pharma Ltd.Inventor: Haya Lorberboum-Galski
-
Patent number: 8912142Abstract: Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide to a subject.Type: GrantFiled: February 28, 2010Date of Patent: December 16, 2014Assignees: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Rappaport Family Institute for Research in the Medical SciencesInventors: Eli Sprecher, Janna Nousbeck
-
Patent number: 8911776Abstract: The present invention relates to novel therapies for treatment of new and existing type 1 and type 2 diabetes, PreDiabetes, Latent Autoimmune Diabetes of Adulthood, and diseases of insulin deficiency, beta cell deficiency, insulin resistance and impaired glucose metabolism. In particular, the present invention identifies common peptides within the human Reg1a, Reg1b, Reg3a and Reg4, as signaling peptides for beta cell generation acting through the human Reg Receptor on the surface of human pancreatic extra-islet tissue.Type: GrantFiled: October 26, 2012Date of Patent: December 16, 2014Inventor: Claresa Levetan
-
Publication number: 20140364360Abstract: A pharmaceutical composition for sustained release of a chemokine is described that includes a polymer bonded to a sulfated glycosaminoglycan and loaded with a chemokine having affinity for the sulfated glycosaminoglycan. The pharmaceutical composition can be used in a method for providing sustained release of a chemokine to subject by contacting the subject with the pharmaceutical composition.Type: ApplicationFiled: June 10, 2014Publication date: December 11, 2014Inventors: Horst A. von Recum, Adonis Hijaz
-
Publication number: 20140364371Abstract: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described.Type: ApplicationFiled: June 5, 2014Publication date: December 11, 2014Inventors: Lori A. Setton, Ashutosh Chilkoti, Virginia B. Kraus, Helawe Betre, Matthew R. Dreher
-
Patent number: 8906863Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.Type: GrantFiled: September 1, 2011Date of Patent: December 9, 2014Assignee: The Regents of the University of CaliforniaInventors: R. Holland Cheng, Li Xing
-
Patent number: 8906365Abstract: The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.Type: GrantFiled: June 28, 2010Date of Patent: December 9, 2014Assignees: Lysando AG, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Rob Lavigne, Stefan Miller, Yves Briers, Guido Volckaert, Maarten Walmagh
-
Patent number: 8906864Abstract: The invention concerns the identification and use of neogenin receptor-binding domains of members of the repulsive guidance molecule (RGM) protein family as well as polypeptide fragments derived therefrom. The inventive domains, i.e. peptide fragments are suited as agents for the active or passive immunization of individuals as well as diagnostic and therapeutic agents for use with diseases or pathological conditions in whose origin or progression, a member of the RGM family and a cellular receptor assigned to this molecule are involved. The invention also concerns monoclonal and polyclonal antibodies directed against the inventive binding domains and against the polypeptides derived therefrom, and to method for producing the inventive domains, polypeptides and antibodies.Type: GrantFiled: September 29, 2006Date of Patent: December 9, 2014Assignee: AbbVie Deutschland GmbH & Co. KGInventors: Bernhard K. Muller, Gregor Schaffar, Reinhold Mueller
-
Patent number: 8906862Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.Type: GrantFiled: August 29, 2011Date of Patent: December 9, 2014Assignees: The Regents of the University of California, National Institute of Infectious Disease, Tsukuba Primate Research Center, National Institue of Biomedical InnovationInventors: R. Holland Cheng, Li Xing, Tatsuo Miyamura, Yasuhiro Yasutomi, Tian-Cheng Li, Naokazu Takeda
-
Publication number: 20140356380Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.Type: ApplicationFiled: December 31, 2013Publication date: December 4, 2014Applicant: NOVIMMUNE S.A.Inventors: Greg Elson, Olivier Leger
-
Publication number: 20140357548Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits IL-4 and/or IL-13 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.Type: ApplicationFiled: December 12, 2012Publication date: December 4, 2014Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
-
Publication number: 20140357576Abstract: The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis by enhancing myofibrillar muscle protein synthesis. The method includes administering to the individual a mixed macronutrient composition having (i) an amount of whey protein that is not capable of enhancing myofibrillar protein synthesis when ingested by itself and (ii) free leucine. The composition comprises at least about 5.0 g total leucine per dose.Type: ApplicationFiled: May 8, 2014Publication date: December 4, 2014Applicant: Nestec S.A.Inventors: Denis BREUILLE, Trent STELLINGWERFF, Daniel Ryan MOORE, Elizabeth Ann OFFORD CAVIN, Stuart Martin PHILLIPS
-
Patent number: 8901076Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: November 3, 2009Date of Patent: December 2, 2014Assignee: Molecular Partner AGInventors: Hans Kasper Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 8901070Abstract: The present disclosure includes methods and compositions for treating any condition involving prostatitis and similar diseases and/or conditions. These methods and compositions involve the use of targeted modified pore-forming proteins, including variant proaerolysin proteins.Type: GrantFiled: September 10, 2012Date of Patent: December 2, 2014Assignee: Sophiris Bio, Corp.Inventor: J. Curtis Nickel
-
Publication number: 20140348832Abstract: The present invention provides a bispecific biologic comprising a ligand specific for CTLA-4 and a ligand specific for a pMHC complex.Type: ApplicationFiled: June 29, 2012Publication date: November 27, 2014Applicant: GENZYME CORPORATIONInventors: Yunxiang Zhu, Jozsef Karman, Ronnie Wei, Canwen Jiang, Seng Cheng
-
Publication number: 20140348827Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: December 19, 2012Publication date: November 27, 2014Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Huiquan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Publication number: 20140349924Abstract: The present invention relates to shelf stable non-aqueous pharmaceutical compositions, and to the use thereof in methods of treating diabetes and hyperglycaemia.Type: ApplicationFiled: July 21, 2014Publication date: November 27, 2014Inventors: Simon Bjerregaard Jensen, Svend Havelund, Florian A. Foeger
-
Publication number: 20140342978Abstract: Charged nutritive proteins are provided. In some embodiments the nutritive proteins an aqueous solubility of at least 12.5 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 50 g/L at pH 7. In some embodiments the nutritive proteins an aqueous solubility of at least 100 g/L at pH 7.Type: ApplicationFiled: July 22, 2014Publication date: November 20, 2014Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Michael Hamill, Rajeev Chillakuru, John F. Kramarczyk
-
Patent number: 8889625Abstract: The present invention provides methods, compositions, and systems for treating a subject at risk for, with, or suspected of having, myocardial ischemia using hepatocyte secretory factors (e.g., AGP2, BMPER, FGF21, NRG4, and/or TFF3) or using factors that promote liver cell migration to ischemic myocardial tissue (e.g., IL-6 and/or MMP-2).Type: GrantFiled: July 9, 2010Date of Patent: November 18, 2014Assignee: Northwestern UniversityInventor: Shu Q. Liu
-
Patent number: 8889632Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.Type: GrantFiled: January 31, 2008Date of Patent: November 18, 2014Assignees: Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard CollegeInventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Susan Korsmeyer
-
Patent number: 8889374Abstract: The present invention relates to recombinant factor H and variants and conjugates thereof and methods of their production, as well as uses and methods of treatment involving the materials.Type: GrantFiled: December 23, 2010Date of Patent: November 18, 2014Assignee: University Court of the University of EdinburghInventors: Christoph Schmidt, Paul N. Barlow, Anna Richards
-
Publication number: 20140336111Abstract: The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatit is and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.Type: ApplicationFiled: January 25, 2013Publication date: November 13, 2014Applicant: Universtität LeipzigInventor: Rolf Gebhardt
-
Publication number: 20140335104Abstract: The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.Type: ApplicationFiled: April 14, 2014Publication date: November 13, 2014Inventors: Mireille Hanna Lahoud, Irina Caminschi, Ken Shortman, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Mark Dexter Wright
-
Publication number: 20140336133Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.Type: ApplicationFiled: July 29, 2014Publication date: November 13, 2014Inventors: Jeffrey C. Miller, Edward J. Rebar, H. Steve Zhang
-
Publication number: 20140335108Abstract: The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis.Type: ApplicationFiled: December 12, 2012Publication date: November 13, 2014Inventors: Kenneth Walsh, Ling Zeng
-
Publication number: 20140335129Abstract: Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins.Type: ApplicationFiled: July 21, 2014Publication date: November 13, 2014Inventors: LĂ©on Mathieu Johannes Knippels, Elisabeth Catharina Adriana Maria van Esch, Johan Garssen
-
Publication number: 20140336126Abstract: The invention relates to Optineurin-derived polypeptide(s) consisting of a polypeptidic sequence disclosed in SEQ ID no2, which represents the portion of the wild-type human Optineurin protein sequence from its amino-acid residue 131 to its amino-acid residue 297, or having a polypeptidic sequence encompassing the polypeptidic sequence disclosed in SEQ ID no2, or having a polypeptidic sequence derived from the polypeptidic sequence disclosed in SEQ ID no2 to the exclusion of the wild-type Optineurin protein. The polypeptide(s) of the invention retain one, any combination of two, or three of the following functional properties: the capacity to bind Rab8 protein, when the latter are associated with the Golgi apparatus of a cell, the capacity to bind MYPT1 protein, when said protein is engaged in a Myosin-Phosphatase (MP) complex, the capacity to be phosphorylated by Plk1.Type: ApplicationFiled: December 18, 2012Publication date: November 13, 2014Inventors: Robert Serge Weil, David Kachaner, Josina Côrte-Real Filipe, Emmanuel François Laplantine, Alain Israël
-
Patent number: 8883971Abstract: The present disclosure relates to CTLA4 proteins and uses of such proteins, for example to treat diseases associated with the dysregulation of immune responses.Type: GrantFiled: August 15, 2013Date of Patent: November 11, 2014Assignee: AbbVie Biotherapeutics Inc.Inventors: Yoshiko Akamatsu, Veronica Juan, Robert B. Dubridge
-
Patent number: 8883732Abstract: A therapeutic method for cardiac diseases such as angina, myocardial infarction, arrhythmia (ventricular tachycardia, ventricular fibrillation and atrial fibrillation) is provided. The method is characterized by intracoronary administration of adiponection to mammals.Type: GrantFiled: March 11, 2013Date of Patent: November 11, 2014Assignee: National University Corporation Nagoya UniversityInventors: Rei Shibata, Toyoaki Murohara
-
Publication number: 20140329764Abstract: The present invention relates to novel therapies that utilize exogenous HSP70 for the treatment of disorders or conditions regulated by HSP70 through administration of exogenous HSP70.Type: ApplicationFiled: July 16, 2014Publication date: November 6, 2014Applicant: Alternative Innovative Technologies LLCInventors: Sergei B. Onikienko, Alex Nivorozhkin, Alexander V. Zemlyanoi
-
Publication number: 20140329756Abstract: Systems and methods for cosmetic augmentation by forming a biocompatible cross-linked polymer having a multi-phase mixture with a temperature activated catalyst; injecting the mixture into a patient as a homogeneous fluid; activating the catalyst to cross-link the polymer at a predetermined temperature in a patient; and augmenting soft tissue with the biocompatible cross-linked polymer.Type: ApplicationFiled: April 18, 2014Publication date: November 6, 2014Applicant: MIBA MEDICAL INC.Inventors: Phi Nguyen, Loc Phan, Bao Tran, Thuan Nguyen
-
Patent number: 8877712Abstract: Methods and compositions are described enhancing bone density or formation, including for stabilizing bone grafts, bone repair, joint replacement, and cartilage repair that includes providing a composition including Del-1 locally to a site for enhancing bone density or formation, or to a culture or chondrocytes or multipotent chondrocyte precursor cells, whereby survival or differentiation of chondrocytes at the site is enhanced, thereby ultimately enhancing bone density or formation. Methods and compositions for stimulating hair regrowth are also provided.Type: GrantFiled: April 6, 2007Date of Patent: November 4, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: George P Yang, Jonathan A. Mathy, Thomas Quertermous
-
Patent number: 8877714Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.Type: GrantFiled: June 14, 2006Date of Patent: November 4, 2014Assignee: Raptor Pharmaceutical Inc.Inventors: Christopher M. Starr, Todd C. Zankel
-
Publication number: 20140322227Abstract: The present invention concerns the use of HYD1 peptides to reduce activated T-cell numbers and/or to promote bone preservation in vivo. The present invention concerns methods of treating a bone deficiency and/or an autoimmune disorder, comprising administering an effective amount of a HYD1 peptide. Another aspect of the invention concerns a pharmaceutical composition comprising a HYD1 peptide and another agent for treating a bone deficiency and/or another agent for treating an autoimmune disorder.Type: ApplicationFiled: April 28, 2014Publication date: October 30, 2014Inventors: LORI HAZLEHURST, MARK MCLAUGHLIN, RAJESH R. NAIR
-
Publication number: 20140322132Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
-
Publication number: 20140323413Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.Type: ApplicationFiled: March 15, 2012Publication date: October 30, 2014Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Gregory Hageman, Yingbin Fu
-
Patent number: 8871723Abstract: An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc.Type: GrantFiled: April 30, 2008Date of Patent: October 28, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Menachem Rubinstein, Ariel Werman, Ben Alkahe
-
Patent number: 8871722Abstract: The present invention provides perhydrolase enzyme CD4+ T-cell epitopes, as well as variants that exhibit reduced immunogenic responses, as compared to the parental perhydrolase. The present invention further provides DNA molecules that encode perhydrolase variants, and host cells comprising DNA encoding perhydrolase variants, as well as methods for making perhydrolase enzymes less immunogenic. In addition, the present invention provides various compositions that comprise perhydrolase variants that are less immunogenic than the wild-type perhydrolase. In some specific embodiments, the present invention provides perhydrolase variants with reduced immunogenicity identified and/or characterized using the methods of the present invention. These enzymes find use in cleaning and other applications. In some preferred embodiments, the present invention finds particular use in applications involving cleaning, bleaching and disinfecting.Type: GrantFiled: December 4, 2006Date of Patent: October 28, 2014Assignee: Danisco US Inc.Inventor: Fiona A. Harding
-
Publication number: 20140314830Abstract: The present invention relates to a new isolated polypeptide nominated microcin S, isolated nucleic acid molecules encoding the microcin S polypeptide and primers and probes hybridizing to the nucleic acid molecules. The invention also relates to plasmids and cells comprising the nucleic acid molecules, an antibody binding to the polypeptide, compositions as well as methods for producing and using the polypeptides. The present invention further relates to medical uses for treating or preventing microbial infections, functional gastrointestinal disorders or treating a tumor. The invention further relates to a method for preserving food and a method for coating dressing material.Type: ApplicationFiled: August 13, 2012Publication date: October 23, 2014Applicant: SYMBIOGRUPPE GMBH & CO. KGInventors: Florian Gunzer, Anke Zschuettig, Kurt Zimmermann
-
Publication number: 20140314859Abstract: It has been found that modification of surfaces of nanoparticles with a RolA protein decreases an immunostimulation activity of the nanoparticles on myeloid dendritic cells and also decreases phagocytosis of the nanoparticles by macrophages. The present invention provides nanoparticles being modified with a biological molecule and having an immune-response evasion function.Type: ApplicationFiled: August 3, 2012Publication date: October 23, 2014Applicant: TOHOKU UNIVERSITYInventors: Keietsu Abe, Kazuyoshi Kawakami, Tadafumi Ajiri, Manabu Fukumoto, Seiichi Takami, Takanari Togashi, Kimihide Muragaki, Toru Takahashi
-
Publication number: 20140314770Abstract: The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.Type: ApplicationFiled: February 5, 2014Publication date: October 23, 2014Applicant: Celera CorporationInventors: Elizabeth JOSELOFF, Steve RUBEN, Tao HE